# Health-Data-Red-Team-Protocol-for-Multimodal-Imaging-Pipelines
This research builds a red-team protocol for multimodal health pipelines, starting with ophthalmology. We create realistic failure scenarios across imaging and clinical metadata, test how LLMs behave under these corruptions, and design mitigation layers so models degrade safely rather than fail dangerously.

## A Systematic Evaluation Framework for Multimodal LLM Robustness in Clinical Settings

**Author:** Jasmin Bharadiya
**Project Duration:** 18 months  
**Start Date:** Q1 2026

---

## Executive Summary

This research project establishes a comprehensive red-teaming framework to systematically evaluate the failure modes of Large Language Models (LLMs) in clinical imaging pipelines. By leveraging lessons from AMD phenotyping quality control, we develop adversarial evaluation protocols that expose critical vulnerabilities in multimodal medical AI systems when confronted with real-world data imperfections.

**Key Innovation:** Transformation of clinical QC protocols into adversarial ML evaluation frameworks that bridge the gap between controlled research environments and messy clinical reality.

---

## 1. Research Motivation & Significance

### 1.1 Problem Statement

Current multimodal LLMs show impressive performance on curated medical imaging benchmarks, yet their deployment in clinical settings reveals systematic failures when encountering:
- Incomplete metadata (30-40% of real-world cases)
- Low-quality images (15-25% of clinical acquisitions)
- Laterality mismatches (2-5% error rate in EHR systems)
- ICD-imaging discordance (10-20% of cases show temporal lag)
- Medication-imaging stage inconsistencies (emerging anti-VEGF effects)

### 1.2 Research Gap

**Current State:** LLM evaluation focuses on accuracy metrics on clean, curated datasets.

**Missing Link:** Systematic characterization of failure modes under realistic data degradation and inconsistencies that mirror clinical workflows.

**Our Contribution:** A structured red-team protocol that:
1. Quantifies LLM robustness across 5 clinical data quality dimensions
2. Maps failure patterns to specific architectural and training decisions
3. Provides actionable insights for improving medical AI reliability

### 1.3 Expected Impact

**Clinical Value:**
- Reduce diagnostic errors from AI systems by 40-60%
- Establish safety protocols for LLM deployment in imaging workflows
- Create trust calibration frameworks for clinician-AI collaboration

**Scientific Value:**
- First systematic taxonomy of multimodal LLM failure modes in medicine
- Benchmark dataset for adversarial medical AI evaluation
- Theoretical framework connecting data quality to model reliability

**Economic Value:**
- Prevent costly misdiagnoses (estimated $750K-$2M per sentinel event)
- Optimize AI deployment strategies (ROI improvement 2-3x)
- Reduce liability exposure for health systems

---

## 2. Research Questions & Hypotheses

### Primary Research Questions

**RQ1:** How do different types of data degradation affect LLM diagnostic accuracy across the clinical imaging pipeline?

**RQ2:** Are certain LLM architectures more robust to specific failure modes than others?

**RQ3:** Can we predict LLM failure patterns based on input data characteristics?

**RQ4:** What interventions (architectural, training, or prompting) most effectively mitigate identified failure modes?

### Hypotheses

**H1:** LLMs will show non-linear degradation curves, with catastrophic failures at specific data quality thresholds rather than gradual decline.

**H2:** Vision-language models with explicit reasoning chains will be more robust to metadata inconsistencies than end-to-end models.

**H3:** Laterality mismatches will cause more severe failures than image quality degradation due to spatial reasoning limitations.

**H4:** Models trained with synthetic data corruption will show 30-50% improved robustness without sacrificing clean-data performance.

**H5:** Ensemble approaches combining multiple data modalities will exhibit graceful degradation under partial information loss.

---

## 3. Methodology

### 3.1 Dataset Construction

#### 3.1.1 Base Dataset
- **Source:** Multi-center AMD imaging database (n=50,000 patients)
- **Modalities:** OCT, fundus photography, FAF
- **Annotations:** Expert-graded severity, geographic atrophy measurements, treatment history
- **Clinical data:** ICD-10 codes, medications, visit notes

#### 3.1.2 Adversarial Transformations

**Dimension 1: Metadata Corruption**
- Missing age (20%, 50%, 80% of samples)
- Missing prior imaging history
- Incomplete medication lists
- Absent or corrupted DICOM headers

**Dimension 2: Image Quality Degradation**
- Gaussian blur (σ = 1, 3, 5, 10 pixels)
- Gaussian noise (SNR: 30dB, 20dB, 10dB, 5dB)
- Motion artifacts (synthetic)
- Compression artifacts (JPEG quality: 90, 70, 50, 30, 10)
- Illumination variations (±20%, ±40% intensity)
- Partial occlusions (10%, 25%, 50% area)

**Dimension 3: Laterality Corruption**
- Swap OD/OS labels (5%, 10%, 20% of cases)
- Missing laterality information
- Cross-patient laterality mixing

**Dimension 4: ICD-Imaging Temporal Discordance**
- ICD codes lagging imaging by 3, 6, 12, 24 months
- ICD overcoding (more severe than imaging)
- ICD undercoding (less severe than imaging)
- Wrong diagnosis codes

**Dimension 5: Medication-Imaging Inconsistency**
- Anti-VEGF treatment without corresponding wet AMD features
- Advanced imaging with no treatment history
- Drug dosing inconsistent with disease stage
- Off-label medication usage

### 3.2 Model Selection & Evaluation

#### 3.2.1 Model Suite
1. **General Multimodal LLMs**
   - GPT-4V, GPT-4o
   - Gemini 1.5 Pro/Flash
   - Claude 3.5 Sonnet, Claude Opus 4
   
2. **Medical-Specific Models**
   - Med-PaLM M
   - LLaVA-Med
   - BiomedCLIP + LLaMA
   
3. **Specialized Vision Models (Baseline)**
   - RETFound
   - Domain-specific CNN architectures

#### 3.2.2 Evaluation Metrics

**Task-Specific Performance:**
- Diagnostic accuracy (multiclass classification)
- Severity grading (ordinal regression, Kendall's τ)
- Geographic atrophy segmentation (Dice, IoU)
- Treatment recommendation alignment (F1, precision, recall)

**Robustness Metrics:**
- Effective robustness: Δ(accuracy) vs. degradation level
- Consistency: prediction variance across perturbations
- Calibration: ECE (Expected Calibration Error) under corruption
- Failure detection: AUROC for predicting wrong answers

**Failure Characterization:**
- Confusion matrices by corruption type
- Error severity distribution
- Silent failure rate (confident but wrong)
- Cascading failure probability

### 3.3 Machine Learning Methods by Research Phase

#### Phase 1: Baseline Characterization (Months 1-3)
**ML Components:**
- **Image preprocessing:** Contrast normalization, registration
- **Feature extraction:** Vision transformer embeddings (DINOv2, CLIP)
- **Benchmark models:** Fine-tuned ResNet50, EfficientNet-B4
- **Statistical analysis:** Mixed-effects models for inter-rater reliability

#### Phase 2: Adversarial Dataset Generation (Months 3-6)
**ML Components:**
- **Synthetic corruption:** Diffusion models for realistic artifacts
- **Metadata simulation:** LLM-generated clinical notes with controlled inconsistencies
- **Quality assessment:** Image Quality Assessment (IQA) networks to validate degradation
- **Stratified sampling:** Clustering to ensure balanced corruption distribution

#### Phase 3: LLM Red-Team Evaluation (Months 6-12)
**ML Components:**
- **Prompt engineering:** Chain-of-thought, few-shot learning, role-playing
- **Attention analysis:** Visualization of which input features drive decisions
- **Uncertainty quantification:** Ensemble disagreement, Monte Carlo dropout
- **Error analysis:** Decision tree classifiers to predict failure modes

#### Phase 4: Robustness Improvement (Months 12-15)
**ML Components:**
- **Data augmentation:** Adversarial training with corrupted samples
- **Multi-task learning:** Joint training on image quality assessment + diagnosis
- **Uncertainty-aware architectures:** Bayesian neural networks, evidential deep learning
- **Test-time adaptation:** Online calibration using metadata reliability scores
- **Retrieval augmentation:** RAG with clean reference cases

#### Phase 5: Validation & Deployment (Months 15-18)
**ML Components:**
- **Prospective validation:** Real-world streaming evaluation
- **Monitoring systems:** Drift detection, out-of-distribution detection
- **Human-AI collaboration:** Confidence-based routing to human experts
- **Continual learning:** Online model updates with human feedback

---

## 4. Detailed Project Roadmap

### Phase 1: Foundation & Baseline (Months 1-3)

**Month 1: Setup & Data Preparation**
- IRB approval and data use agreements
- Database curation and quality checks
- Establish annotation protocols
- Literature review and related work analysis

**Deliverables:**
- Annotated clean dataset (n=10,000 cases)
- Baseline model performance report
- Protocol paper draft

**Month 2: AMD QC Funnel Adaptation**
- Map AMD phenotyping QC steps to adversarial evaluation
- Develop corruption taxonomy
- Build data pipeline infrastructure
- Implement baseline models

**Deliverables:**
- QC-to-red-team mapping document
- Adversarial transformation library
- Baseline model benchmarks

**Month 3: Pilot Red-Team Study**
- Small-scale evaluation (n=1,000 cases, 3 models)
- Validate corruption protocols
- Refine metrics and evaluation framework
- Initial failure mode analysis

**Deliverables:**
- Pilot study results
- Revised research protocol
- Conference abstract submission (ARVO, MICCAI)

---

### Phase 2: Adversarial Dataset Construction (Months 3-6)

**Month 4: Automated Corruption Pipeline**
- Scale up adversarial transformations
- Implement quality control for synthetic corruptions
- Develop metadata simulation framework
- Create corruption severity calibration

**Deliverables:**
- Full adversarial dataset (n=50,000 cases × 5 dimensions × 5 levels)
- Data quality validation report
- Open-source corruption toolkit

**Month 5: Multi-Modal Inconsistency Generation**
- Clinical note generation with controlled inconsistencies
- Temporal misalignment simulation
- Cross-modal conflict injection
- Expert validation of realism

**Deliverables:**
- Multi-modal adversarial dataset
- Clinical validation study results
- Data descriptor manuscript

**Month 6: Dataset Documentation & Release**
- Comprehensive dataset documentation
- Benchmark task definitions
- Baseline leaderboard establishment
- Public dataset release preparation

**Deliverables:**
- Dataset paper submission (Nature Scientific Data, NeurIPS Datasets Track)
- Public benchmark website
- Data access portal

---

### Phase 3: Comprehensive LLM Red-Team Evaluation (Months 6-12)

**Month 7-8: Single-Dimension Evaluation**
- Systematic evaluation per corruption dimension
- Dose-response curves for each degradation
- Model comparison across architectures
- Failure mode taxonomy development

**Deliverables:**
- Single-dimension robustness profiles
- Model ranking by dimension
- Failure taxonomy v1.0

**Month 9-10: Multi-Dimensional Interaction Study**
- Combined corruption scenarios
- Interaction effect analysis
- Catastrophic failure detection
- Cascading error analysis

**Deliverables:**
- Interaction effects paper draft
- Critical failure threshold identification
- Safety guideline recommendations

**Month 11-12: Mechanistic Failure Analysis**
- Attention visualization studies
- Ablation experiments
- Causal tracing of errors
- Theoretical failure mode modeling

**Deliverables:**
- Mechanistic analysis manuscript (ICLR, ICML)
- Failure prediction model
- Interpretability toolkit

---

### Phase 4: Robustness Enhancement (Months 12-15)

**Month 13: Adversarial Training**
- Implement corruption-robust training
- Multi-task learning with quality assessment
- Compare training strategies
- Evaluate generalization

**Deliverables:**
- Robustness-enhanced model checkpoints
- Training protocol documentation
- Ablation study results

**Month 14: Architecture & Prompting Optimization**
- Test architectural modifications
- Prompt engineering experiments
- Uncertainty quantification integration
- Ensemble method development

**Deliverables:**
- Optimized model architectures
- Prompt library for robust inference
- Ensemble framework

**Month 15: Validation on Hold-Out Data**
- External validation on independent datasets
- Prospective study simulation
- Clinical expert evaluation
- Safety assessment

**Deliverables:**
- Validation study report
- Clinical utility assessment
- Regulatory documentation prep

---

### Phase 5: Deployment Framework & Dissemination (Months 15-18)

**Month 16: Clinical Decision Support Integration**
- Prototype deployment system
- Human-AI collaboration interface
- Real-time monitoring dashboard
- Alert system for high-risk predictions

**Deliverables:**
- Deployment-ready prototype
- User interface mockups
- System design document

**Month 17: Prospective Pilot Study**
- Limited clinical deployment (1-2 sites)
- Real-world performance monitoring
- Clinician feedback collection
- Iterative refinement

**Deliverables:**
- Pilot study results
- User feedback report
- System improvements v2.0

**Month 18: Dissemination & Knowledge Transfer**
- Final manuscript submissions
- Conference presentations
- Workshop organization
- Open-source toolkit release

**Deliverables:**
- Primary research paper (Nature Medicine, NEJM AI)
- Methods paper (JAMA Network Open)
- Public code repository
- Tutorial documentation

---

## 5. Research Findings (Projected)

### 5.1 Quantitative Findings

**Finding 1: Non-Linear Degradation**
- LLMs maintain >90% accuracy until critical corruption thresholds
- Catastrophic failure occurs at:
  - Image SNR < 15dB (accuracy drops to ~40%)
  - >30% metadata missing (accuracy drops to ~50%)
  - Laterality mismatch causes immediate 60-80% error rate

**Finding 2: Failure Mode Taxonomy**
- **Type I: Silent Failures (35%)** - Confident but wrong predictions
- **Type II: Inconsistent Reasoning (25%)** - Contradictory explanations
- **Type III: Hallucination (20%)** - Seeing features not present
- **Type IV: Refusal Errors (15%)** - Inappropriate abstention
- **Type V: Cascading Errors (5%)** - One error triggers multiple downstream failures

**Finding 3: Model Architecture Matters**
- Vision-language models with explicit reasoning: 40% more robust to metadata issues
- End-to-end models: 35% more robust to image quality degradation
- Retrieval-augmented models: 50% better at handling medication inconsistencies

**Finding 4: Adversarial Training Benefits**
- +35% robustness to trained corruption types
- +15% generalization to unseen corruptions
- -3% clean data performance (acceptable trade-off)

**Finding 5: Predictable Failure Patterns**
- 85% of failures predictable from input data quality metrics
- Uncertainty estimates correlate with errors (AUROC 0.82)
- Multi-modal inconsistency is strongest failure predictor

### 5.2 Qualitative Insights

**Insight 1: Overreliance on Text**
LLMs disproportionately weight clinical notes over images when conflicts arise, even when images are higher quality—reflecting training data biases.

**Insight 2: Spatial Reasoning Brittleness**
Laterality confusion reveals fundamental limitations in spatial grounding, not just label processing errors.

**Insight 3: Temporal Reasoning Gaps**
Models struggle to reason about disease progression over time, treating each encounter independently.

**Insight 4: Calibration Under Uncertainty**
LLMs become overconfident when data is ambiguous or conflicting, rather than appropriately uncertain.

**Insight 5: Explanation-Performance Dissociation**
Chain-of-thought reasoning can be correct even when final answers are wrong, and vice versa—explanations are not always faithful to decision processes.

---

## 6. Values & Ethical Considerations

### 6.1 Research Values

**Scientific Rigor:**
- Pre-registered hypotheses and analysis plans
- Blinded evaluation where possible
- Multiple validation datasets
- Transparent reporting of negative results

**Reproducibility:**
- Open-source code and evaluation frameworks
- Public dataset release (with appropriate privacy protections)
- Detailed documentation of methods
- Model checkpoints and training logs

**Clinical Relevance:**
- Continuous clinician involvement
- Real-world deployment considerations
- Focus on actionable insights
- Patient safety as primary outcome

**Equity & Fairness:**
- Stratified analysis by patient demographics
- Assessment of disparate impact across subgroups
- Accessibility considerations in deployment
- Global health perspective (low-resource settings)

### 6.2 Ethical Safeguards

**Patient Privacy:**
- Full de-identification per HIPAA/GDPR
- Synthetic data for public release when possible
- Secure data enclaves for sensitive information
- Regular privacy audits

**Responsible AI Development:**
- Red-teaming as proactive safety measure
- Transparency about limitations
- Clear documentation of failure modes
- Guidelines for appropriate use

**Clinical Validation:**
- Prospective validation before any deployment
- Physician oversight in pilot studies
- Clear demarcation of AI vs. human roles
- Emergency stop mechanisms

**Benefit-Risk Assessment:**
- Continuous monitoring of outcomes
- Adverse event reporting
- Comparison to standard of care
- Equitable access to benefits

---

## 7. Impact Pathways

### 7.1 Immediate Impact (0-2 years)

**Academic Community:**
- New evaluation paradigm for medical AI
- Benchmark dataset driving research
- 15-20 publications in top venues
- Workshop series at major conferences

**Industry:**
- Adoption of red-team protocols by AI companies
- Integration into model development pipelines
- Improved safety documentation for FDA submissions
- Commercial partnerships for deployment

**Clinical Practice:**
- Pilot deployments at 3-5 health systems
- Safety guidelines for AI-assisted diagnosis
- Training programs for clinician-AI collaboration
- Quality assurance protocols

### 7.2 Medium-Term Impact (2-5 years)

**Healthcare Systems:**
- Reduced diagnostic errors by 40-60%
- Cost savings from prevented misdiagnoses (~$50M across early adopters)
- Improved physician satisfaction with AI tools
- Expansion to other imaging domains (radiology, pathology)

**Regulatory:**
- Influence FDA guidelines for AI/ML medical devices
- Contribute to international standards (ISO, IEC)
- Evidence base for adaptive AI policies
- Framework for post-market surveillance

**Research Community:**
- 100+ citations and derivative works
- Extension to other medical specialties
- Adoption in non-medical domains (autonomous vehicles, finance)
- New theoretical frameworks for robustness

### 7.3 Long-Term Impact (5-10 years)

**Transformation of Medical AI:**
- Robustness-first design paradigm
- Standardized red-teaming in clinical AI
- Trustworthy AI as competitive differentiator
- Global reduction in AI-related medical errors

**Societal:**
- Increased public trust in medical AI
- Democratization of expert-level diagnostics
- Reduced healthcare disparities
- Economic benefits (~$500M-$1B cost avoidance)

**Scientific Legacy:**
- Foundational methodology for adversarial evaluation
- Training ground for next generation of medical AI researchers
- Interdisciplinary model for clinical-ML collaboration
- Open-source tools used by thousands of researchers

---

## 8. Risk Mitigation

### 8.1 Technical Risks

**Risk:** Dataset biases limit generalizability
**Mitigation:** Multi-center data collection, diverse patient populations, external validation

**Risk:** Adversarial examples don't reflect real corruptions
**Mitigation:** Expert validation, retrospective analysis of real errors, prospective testing

**Risk:** Models overfit to specific corruption types
**Mitigation:** Hold-out corruption types, cross-domain evaluation, regularization techniques

### 8.2 Clinical Risks

**Risk:** Findings discourage AI adoption
**Mitigation:** Balanced reporting, comparison to human performance, emphasize improvement pathways

**Risk:** Red-team data could be misused to attack systems
**Mitigation:** Responsible disclosure, collaboration with vendors, phased public release

**Risk:** Pilot studies cause patient harm
**Mitigation:** Human oversight, safety monitoring, conservative deployment, IRB oversight

### 8.3 Operational Risks

**Risk:** Insufficient data access
**Mitigation:** Backup data sources, partnerships with health systems, synthetic data generation

**Risk:** Computational resource constraints
**Mitigation:** Cloud computing credits, GPU cluster access, algorithmic optimizations

**Risk:** Key personnel turnover
**Mitigation:** Cross-training, documentation, collaborative structure, succession planning

---

## 9. Success Metrics

### 9.1 Academic Success

- ✅ 3+ publications in Nature/Science/Cell family journals
- ✅ 10+ publications in ML conferences (NeurIPS, ICML, ICLR)
- ✅ 5+ publications in medical journals (NEJM AI, Nature Medicine)
- ✅ 500+ citations within 3 years
- ✅ Best paper award at major venue
- ✅ Invited talks at 10+ institutions

### 9.2 Clinical Impact

- ✅ Pilot deployment at 3+ health systems
- ✅ 40%+ reduction in AI diagnostic errors
- ✅ Physician satisfaction >4.0/5.0 with AI tools
- ✅ Zero serious adverse events in pilot studies
- ✅ Adoption by 2+ commercial AI vendors
- ✅ FDA/EMA guideline influence

### 9.3 Community Adoption

- ✅ 1,000+ GitHub stars on toolkit
- ✅ Dataset downloaded by 100+ research groups
- ✅ 10+ derivative research projects
- ✅ Red-team protocol adopted by 5+ companies
- ✅ Workshop with 100+ attendees
- ✅ Tutorial sessions at 3+ conferences

### 9.4 Funding & Sustainability

- ✅ Follow-on funding secured (NIH R01, industry contracts)
- ✅ 3+ commercial partnerships
- ✅ Spin-off company or licensing deals
- ✅ Training program generates revenue
- ✅ Consulting engagements with health systems

---

## 10. Dissemination Strategy

### 10.1 Academic Venues

**Primary Targets:**
- Nature Medicine, NEJM AI (clinical impact)
- Nature Machine Intelligence, Science Robotics (methods)
- NeurIPS, ICML, ICLR (ML foundations)
- MICCAI, IPMI (medical imaging)
- ARVO, Ophthalmology (domain-specific)

**Timeline:**
- Q2 2026: First conference abstracts (ARVO, MICCAI)
- Q3 2026: Dataset paper submission
- Q1 2027: Primary methods paper submission
- Q3 2027: Clinical validation paper submission
- Q4 2027: Capstone Nature Medicine paper

### 10.2 Industry Engagement

- Quarterly workshops with AI/ML companies
- Participation in FDA working groups
- Industry advisory board (Google Health, Microsoft, Anthropic)
- Collaborative evaluation of commercial models
- Licensing discussions for deployment toolkit

### 10.3 Clinical Community

- Grand rounds presentations at 10+ institutions
- CME-accredited webinar series
- Ophthalmology society symposia (AAO, ARVO)
- Policy briefs for clinical leadership
- Training materials for AI-assisted diagnosis

### 10.4 Public & Patient Engagement

- Patient advisory board for study design
- Plain-language research summaries
- Media engagement (press releases, interviews)
- Social media presence (@HealthAI_RedTeam)
- Public dataset portal with educational materials

---

## 11. Future Directions

### 11.1 Extensions of Current Work

**Expansion to Other Domains:**
- Diabetic retinopathy screening
- Glaucoma progression monitoring
- Radiology (chest X-ray, CT, MRI)
- Dermatology image classification
- Pathology slide analysis

**Deeper Mechanistic Studies:**
- Neuroscience-inspired interpretability
- Causal models of LLM decision-making
- Theoretical bounds on robustness
- Cross-modal attention mechanisms

**Advanced Interventions:**
- Continual learning from clinical feedback
- Active learning for edge cases
- Federated learning for privacy-preserving robustness
- Human-in-the-loop correction mechanisms

### 11.2 Novel Research Directions

**Adversarial Defense:**
- Certified robustness for medical AI
- Adversarial detection systems
- Backdoor removal in medical models
- Privacy-preserving red-teaming

**Clinical Workflow Integration:**
- Context-aware AI assistants
- Multi-timestep reasoning models
- Cross-specialty consultation systems
- Uncertainty-driven clinical trial enrollment

**Global Health Applications:**
- Low-resource setting adaptations
- Smartphone-based screening with robustness guarantees
- Telemedicine AI with variable connectivity
- Cross-population generalization

### 11.3 Long-Term Vision

**Trustworthy Medical AI Ecosystem:**
- Standardized evaluation frameworks across specialties
- Regulatory-approved deployment protocols
- Continuous monitoring and improvement systems
- Patient-centered AI design principles

**Research Infrastructure:**
- National red-team evaluation center
- Open-source robustness toolkit suite
- Collaborative benchmarking consortium
- Training programs for next-generation researchers

---

## 12. Conclusion

This research project establishes a comprehensive framework for evaluating and improving the robustness of multimodal LLMs in clinical imaging pipelines. By systematically red-teaming these systems across five critical dimensions of real-world data quality, we will:

1. **Quantify** the vulnerability of current medical AI systems to realistic corruptions
2. **Characterize** failure modes to enable targeted improvements
3. **Develop** adversarial training protocols that enhance robustness
4. **Validate** improvements in prospective clinical settings
5. **Disseminate** methods and tools to transform medical AI development

The expected outcomes—a 40-60% reduction in AI diagnostic errors, new safety protocols for clinical deployment, and a paradigm shift toward robustness-first medical AI—represent a significant advance in trustworthy healthcare AI.

**This research bridges the critical gap between impressive benchmark performance and reliable clinical deployment, ensuring that medical AI systems can handle the messy reality of healthcare data while maintaining patient safety.**

---

## Appendices

### Appendix A: Detailed Literature Review
[To be completed with comprehensive review of adversarial ML, medical AI, and robustness testing]

### Appendix B: Data Management Plan
[Detailed protocols for data storage, security, sharing, and long-term preservation]

### Appendix C: Statistical Analysis Plan
[Pre-registered analysis protocols, power calculations, multiple comparison corrections]

### Appendix D: Institutional Approvals
[IRB protocols, data use agreements, industry collaboration agreements]

### Appendix E: Code & Data Availability
[GitHub repositories, dataset access procedures, reproducibility documentation]

### Appendix F: Team Expertise
[Detailed CVs, relevant publications, prior collaborative work]

---

**Document Version:** 1.0  
**Last Updated:** November 13, 2025  
**Status:** Ready for PI review and grant submission preparation